Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LentinexHP
- Development stage
- Unknown
- Lead developer
- GlycaNova
- Administration
- Oral
01
Overview
LentinexHP is an **undenatured beta-glucan solution** evaluated as an *oral, add-on non-drug therapy* to improve quality of life in patients with stage IV metastatic colorectal cancer[5][3]. Beta-glucans are naturally occurring polysaccharides known for their immunomodulatory activity—primarily through activation of components of the innate immune system, such as macrophages, neutrophils, and natural killer (NK) cells. LentinexHP is being studied for its ability to enhance patient well-being during chemotherapy regimens[1][3][5]. The product's formulation targets support of immune function and mitigation of treatment-related fatigue and reduced quality of life during cancer treatment. The clinical sponsor and likely manufacturer is GlycaNova AS[3].
- Brand names
- LentinexHP
Beyond the preview
Go deeper on LentinexHP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LentinexHP.